Human-murine chimeric antibodies against respiratory syncytial virus
This invention relates to a human antibody which contains the one CDR from each variable heavy and variable light chain of at least one murine monoclonal antibody, against respiratory syncytial virus which is MAb1129 and the use thereof for the prevention and/or treatment of RSV infection.
1. A method of neutralizing respiratory syncytial virus (RSV), comprising administering to a human in need thereof an effective amount of a humanized anti-RSV antibody comprising
(a) a variable heavy chain polypeptide comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 43, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 44, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 45; and
a variable light chain polypeptide comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 46, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 47, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 48; or
(b) a variable heavy chain polypeptide and a variable light chain polypeptide, wherein the variable heavy chain polypeptide sequence is SEQ ID NO:31 and the variable light chain polypeptide sequence is SEQ ID NO:34.
2. A method of neutralizing respiratory syncytial virus (RSV), comprising administering to a human in need thereof a pharmaceutical composition comprising an effective amount of a humanized anti-RSV antibody in conjunction with an acceptable pharmaceutical carrier, wherein the humanized anti-RSV antibody comprises:
(a) a variable heavy chain polypeptide comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 43, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 44, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 45; and
a variable light chain polypeptide comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 46, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 47, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 48; or
(b) a variable heavy chain polypeptide and a variable light chain polypeptide, wherein the variable heavy chain polypeptide sequence is SEQ ID NO:31 and the variable light chain polypeptide sequence is SEQ ID NO:34.
3. The method of claim 1 , wherein the humanized anti-RSV antibody comprises:
(a) a variable heavy chain polypeptide comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 43, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 44, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 45; and
(b) a variable light chain polypeptide comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 46, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 47, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 48.
4. The method of claim 1 , wherein the humanized anti-RSV antibody comprises a variable heavy chain polypeptide and a variable light chain polypeptide, wherein the variable heavy chain polypeptide sequence is SEQ ID NO:31 and the variable light chain polypeptide sequence is SEQ ID NO:34.
5. The method of claim 2 , wherein the humanized anti-RSV antibody comprises:
(a) a variable heavy chain polypeptide comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 43, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 44, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 45; and
(b) a variable light chain polypeptide comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 46, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 47, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 48.
6. The method of claim 2 , wherein the humanized anti-RSV antibody comprises a variable heavy chain polypeptide and a variable light chain polypeptide, wherein the variable heavy chain polypeptide sequence is SEQ NO:31 and the variable light chain polypeptide sequence is SEQ ID NO:34.
7. The method of claim 3 , wherein the humanized antibody is administered intramuscularly.
8. The method of claim 4 , wherein the humanized antibody is administered intramuscularly.
9. The method of claim 5 , wherein the pharmaceutical composition is administered intramuscularly.
10. The method of claim 6 , wherein the pharmaceutical composition is administered intramuscularly.